Ken Griffin Ptc Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,731,025 shares of PTCT stock, worth $130 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,731,025
Previous 920,493
88.05%
Holding current value
$130 Million
Previous $45 Million
136.3%
% of portfolio
0.02%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding PTCT
# of Institutions
325Shares Held
83.2MCall Options Held
811KPut Options Held
207K-
Vanguard Group Inc Valley Forge, PA8.29MShares$624 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.77MShares$585 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.75MShares$583 Million6.35% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$370 Million0.06% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$284 Million0.11% of portfolio
About PTC THERAPEUTICS, INC.
- Ticker PTCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,541,000
- Market Cap $5.39B
- Description
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...